Scott Millen | CNBC
The company is set to release key late-stage trial data on the drug, orforglipron, by the middle of this year.
Eli Lilly is pushing to market the pill as its competition. Novo Nordisk And small competitors for a large part of the weight loss drug market on the rise. Eli Lilly’s Zip Bound And Novo Nordisk’s Wegovy dominates the space, but drugmakers and their rivals are working to grow. Improved version of drugs.
Tablets will be more convenient for patients than current injection forms. They would also be easier to produce at a time when Eli Lilly and Novo Nordisk have struggled to make enough drugs to keep up with rising demand.
Eli Lilly has said that orforglipron helped patients lose up to 14.7 percent of their weight in a mid-stage trial, compared to 2.3 percent in people taking a placebo.
Shares of Eli Lilly were down less than 1 percent in Monday afternoon trading.